Sanara MedTech (SMTI) Earnings Analysis
Sanara MedTech (SMTI) next reports earnings on 2026-08-12, consensus EPS -0.07 USD. Last quarter (2026-05-11) it beat with EPS 0.04 USD vs -0.04 USD est (+200%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E -6.55.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SMTI next report earnings?
| Next earnings date | 2026-08-12 |
|---|---|
| Consensus EPS estimate | -0.07 USD |
| Revenue estimate | 0.03B |
SMTI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | 0.04 USD | -0.04 USD | +200% | Beat |
| 2026-03-24 | 0.04 USD | 0.11 USD | -63.6% | Miss |
| 2025-11-12 | 0.09 USD | -0.24 USD | +137.5% | Beat |
| 2025-08-13 | -0.23 USD | -0.33 USD | +30.3% | Beat |
| 2024-08-12 | -0.41 USD | -0.21 USD | -95.2% | Miss |
Beat rate: 3/5 (60%) over reported quarters with consensus data.
SMTI valuation and analyst view
| Trailing P/E | -6.55 |
|---|---|
| Trailing EPS | -3.8564 USD |
| Price / book | 31.64 |
| Dividend yield | 0.00% |
| Market cap | 0.23B |
| Analyst consensus | Buy (3 buy / 0 hold / 0 sell) |
| Avg price target | 43 USD |
Related research pages
Frequently asked questions
When is Sanara MedTech (SMTI)'s next earnings date?
Sanara MedTech is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.07 USD and revenue estimate of 0.03B.
Did SMTI beat earnings last quarter?
In its 2026-05-11 report, SMTI posted EPS of 0.04 USD versus a -0.04 USD estimate — a beat of 200%.
What is SMTI's earnings track record?
Over the last 5 reported quarters with consensus data, SMTI beat estimates 3 times (60%).
What is SMTI's current P/E ratio and EPS?
SMTI trades at a trailing P/E of -6.55 on trailing EPS of -3.856404474818065 USD.
What do analysts rate SMTI?
Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 43 USD.